Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SUPN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Asset Impairment (new) — The company recorded a $54.9 million non-cash intangible asset impairment charge for APOKYN in Q2 2026, reflecting significant commercial deterioration as sales fell 51% year-over-year.
Supernus reports 32% Q2 revenue growth, raises 2026 guidance, announces merger with Indivior
Filed August 3, 2026 · Period ending August 3, 2026 · ~1 min read
Key Changes
-
high
Q2 2026 revenues rose 32% to $219.1M driven by growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO), but company posted $58.4M net loss ($1.01/share) vs. $22.5M profit in Q2 2025 due to $54.9M APOKYN impairment charge and higher SG&A.
Item 2.02 verify on EDGAR → -
high
Entered definitive agreement for all-stock merger of equals with Indivior Pharmaceuticals to create diversified CNS biopharmaceutical company; transaction subject to stockholder and regulatory approvals.
Item 2.02 verify on EDGAR → -
high
Raised full-year 2026 revenue guidance to $860-890M (from $840-870M) and adjusted operating earnings to $150-180M (from $140-170M) on stronger growth product performance.
Exhibit 99.1 view on EDGAR → -
medium
Recorded $54.9M non-cash intangible asset impairment for APOKYN as sales declined 51% year-over-year to $6.3M in Q2, signaling significant commercial erosion.
Exhibit 99.1 view on EDGAR → -
high
Four growth products generated combined revenues of $175.7M in Q2 2026, up 52% year-over-year, with Qelbree at $89.2M (+15%), ZURZUVAE collaboration revenue at $35.4M, and ONAPGO at $13.5M.
Exhibit 99.1 view on EDGAR →
Summary
Supernus reported strong Q2 2026 revenue growth of 32% to $219.1 million, driven by its four growth products which collectively grew 52% to $175.7 million. However, the company posted a $58.4 million net loss ($1.01 per share) compared to a $22.5 million profit in Q2 2025, primarily due to a $54.9 million intangible asset impairment charge for APOKYN.
The impairment reflects a concerning 51% year-over-year decline in APOKYN sales to just $6.3 million, signaling significant commercial erosion for this legacy product. The company raised its full-year 2026 revenue guidance to $860-890 million and adjusted operating earnings guidance to $150-180 million, reflecting confidence in its growth trajectory.
Supernus also announced a definitive agreement for an all-stock merger of equals with Indivior Pharmaceuticals, intended to create a diversified CNS biopharmaceutical company with greater scale. The transaction requires stockholder and regulatory approvals. Retail investors should monitor the APOKYN impairment as a signal of accelerating legacy product decline, even as growth products offset the erosion. The merger with Indivior represents a strategic pivot that will reshape the company's portfolio and competitive position, pending approvals.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On August 3, 2026, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the second quarter ended June 30, 2026.
Supernus disclosed its financial results for the second quarter ended June 30, 2026 via press release. The 8-K does not provide specific figures for revenue, earnings, or other metrics; those details are in the attached Exhibit 99.1 press release.
Added in current filing · verify on EDGAR →
As previously announced, Supernus and Invidior Pharmaceuticals, Inc. ("Invidior") have entered into a definitive agreement to combine in an all-stock merger of equals (the "Merger").
Supernus confirmed it has entered into a definitive agreement for an all-stock merger of equals with Indivior Pharmaceuticals. The 8-K references the transaction but does not disclose new terms or timing; it notes that a joint proxy statement/prospectus will be filed with the SEC when available.
Added in current filing · verify on EDGAR →
Supernus and Indivior will host a joint conference call and webcast presentation today, August 3, 2026, at 8:30 a.m. EDT. A live webcast will be available in the Investor Relations sections of the Supernus and Indivior websites, and a replay will be available following the event.
The companies scheduled a joint conference call and webcast for August 3, 2026 at 8:30 a.m. EDT to discuss the Q2 results and merger. An investor presentation is also available on both companies' websites.
Event · Exhibit 99.1
Supernus reported Q2 2026 results with 32% revenue growth, raised full-year guidance, and announced a merger agreement with Indivior Pharmaceuticals.
Added in current filing · view on EDGAR → · paraphrased
a non-cash $54.9 million intangible asset impairment charge related to APOKYN in the second quarter of 2026 ... APOKYN $6.3 $12.8 (51)% $14.0 $27.8 (49)%
Supernus recorded a $54.9 million non-cash intangible asset impairment charge for APOKYN in Q2 2026. APOKYN net sales declined 51% year-over-year to $6.3 million in Q2 2026 and 49% to $14.0 million for the first half of 2026, indicating significant erosion in this product's commercial performance.
Added in current filing · view on EDGAR → · paraphrased
Combined revenues of the Company's four growth products increased to $175.7 million in the second quarter 2026, representing an increase of 52% compared to the same period last year. This strong growth was driven by an increase in net sales of Qelbree®, GOCOVRI®, ZURZUVAE®, and ONAPGO™. ... Net sales of Qelbree increased 15% to $89.2 million in the second quarter of 2026 ... Collaboration revenue from ZURZUVAE was $35.4 million in the second quarter of 2026. ... ONAPGO net product sales were $13.5 million in the second quarter of 2026.
The company's four growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) generated combined revenues of $175.7 million in Q2 2026, up 52% year-over-year. Qelbree sales grew 15% to $89.2 million, ZURZUVAE collaboration revenue was $35.4 million (representing 50% of Biogen's net revenues), and ONAPGO contributed $13.5 million. These products are driving the company's overall revenue growth and offsetting declines in legacy products.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 4, 2026 · How we verify